Form 4: LIGAND PHARMACEUTICALS CFO Sells Shares

LIGAND PHARMACEUTICALS' Chief Financial Officer, Octavio Espinoza, reported the sale of 1,804 shares of common stock for $188.31 per share.

Summary

• Octavio Espinoza, Chief Financial Officer of LIGAND PHARMACEUTICALS INC, reported a transaction involving company common stock.
• The transaction, dated December 12, 2025, was a sale of 1,804 shares.
• The shares were disposed of at a price of $188.31 per share.
• Following this transaction, Octavio Espinoza directly beneficially owns 26,186 shares of LIGAND PHARMACEUTICALS INC common stock.

Sentiment

Score: 4

Explanation: The Chief Financial Officer sold a portion of their holdings, which can sometimes be interpreted as a lack of confidence, though it's a common occurrence for executives to diversify or manage personal finances. The amount sold is not exceptionally large relative to total holdings.

Negatives

• Chief Financial Officer Octavio Espinoza sold 1,804 shares of company common stock, which can sometimes be perceived negatively by investors.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the sale by a key executive as a potential signal regarding the company's future prospects, though the amount sold is moderate.

Key Dates

Recommendation

While the CFO sold shares, this is a routine disclosure and the amount sold represents a relatively small portion of their total beneficial ownership. Without further context on the company's performance or other insider activity, this single transaction does not warrant a change from a 'hold' position. Investors should monitor future insider activity and company fundamentals.

Keywords

LIGAND PHARMACEUTICALS, LGND, Octavio Espinoza, CFO, Insider Trading, Stock Sale, Form 4, Beneficial Ownership